Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights

Executive Summary

Agios Pharmaceuticals Inc. will get $200m to kick off a new partnership with longtime collaborator Celgene Corp. under a complex agreement to develop therapies that alter the metabolic state of immune cells to enhance the immune response to cancer.

Advertisement

Related Content

Agios, Celgene Target Accelerated Approvals For Precision AML Medicines
Biopharma Quarterly Dealmaking Statistics, Q2 2016
ASH 2015: First-In-Class Myeloma Highlights
Celgene and Agios to target cancer metabolism in $250 million deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel